As IRAK4 signaling was also thought to be a mechanism of adaptive resistance in the setting of FLT3‐mutant AML,152 a phase I/II trial of Emavusertib, a novel oral dual IRAK4 and FLT3 inhibitor, was undertaken in patients with R/R MDS/AML. Here, IRAK4 is linked to acute myeloid leukemia.